Monday, September 14, 2026

South Korea’s Used Car Exports Plummet 28.7%: What Does the Future Hold After U.S.-Iran Peace Deal?

The U.S.-Iran peace accord may revive South Korea's used car exports, but challenges like high shipping costs and inventory backlog remain.

SK Hynix IPO: Record-Breaking 26.5 Billion USD Offering on Nasdaq – What Investors Need to Know

SK Hynix's IPO at $149 per share raises $26.5B, marking the largest foreign IPO in U.S. history, fueled by strong AI market demand.

Japan’s Pension Fund to Invest 1% in Digital Assets: What This Means for the Future of Crypto

Japan's corporate pension funds will invest in digital assets, diversifying portfolios as regulations for cryptocurrencies advance.

Tag: Oncology

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

YH42946: The Promising HER2 Targeted Oral Treatment Set to Transform Cancer Care in 2026

Yuhan Corporation will reveal early results of its oral HER2-targeted therapy candidate 'YH42946' in clinical trials by year-end.

CS5001 Breakthrough: 100% Complete Remission in DLBCL Trials – What This Means for Cancer Treatment

ABL Bio's ADC candidate shows complete response in all patients in early trials for first-line treatment of DLBCL.

Revolutionary Cancer Drug Penitrium Shows Promise in Restoring Chemotherapy Effectiveness

Pennitrium Bioscience has confirmed the potential of a new drug candidate to enhance the effectiveness of existing cancer treatments.

PenetriumBioScience Files U.S. FDA IND for Phase 2a Trial in Advanced Solid Tumors

Penitrium Bioscience enters Phase 2a clinical trials in the U.S. for its cancer drug candidate 'Penitrium.'

Revolutionary In Situ Cancer Vaccines: Can They Cure Relapsed and Metastatic Cancer?

Inha University reveals a next-gen immunotherapy strategy using tumors from patients to treat relapsed and metastatic cancers.

HLB PEP Achieves FDA Registration for Vasopressin API: What This Means for Global Markets

HLB PEP has registered Vasopressin API with the FDA, aiming for global market entry and expanding its peptide portfolio.

Hanmi Pharmaceutical completes acquisition of Aptose Biosciences

Hanmi Pharmaceutical has acquired Aptose Biosciences for $46.7 million, regaining rights to the cancer drug tuspetinib.

Celltrion’s Truxima becomes first rituximab biosimilar in U.S. to receive interchangeability designation

Celltrion's Truxima gains FDA interchangeability status, enhancing its market position and credibility in blood cancer treatment.

LegoChem expands options beyond early ADC licensing into late-stage clinical development

LegoChem Biosciences secures funding to advance ADC therapies into late-stage trials, enhancing strategic flexibility in biotech.

Seoul Asan Hospital Dominates Newsweek’s 2026 Asia-Pacific Rankings: 5 Clinical Areas at #1!

Seoul Asan Medical Center ranks first in five specialties in Newsweek's 2026 Asia-Pacific Best Hospitals, showcasing its medical excellence.

Celltrion Launches New Cancer Drugs in Vietnam: What You Need to Know

Celltrion launched two cancer treatments in Vietnam, expanding its portfolio and aiming for aggressive sales growth in the region.

ABL Bio to Showcase Dual-Target ADC Candidate ABL209 at World ADC Korea 2026

ABL Bio will showcase its dual-target ADC candidate ABL209 at the World ADC Korea 2026, focusing on enhanced cancer treatment.

Sillajen Presents Early BAL0891 Clinical Findings at ASCO 2026, Highlighting Safety and Early Anti-Cancer Activity

ShillaGen presented initial clinical research results of its cancer drug BAL0891 at ASCO, showcasing promising developments.

FDA Approval Allows AlphaTau to Broaden IMPACT Trial in Pancreatic Cancer

AlphaTau Medical expands its pancreatic cancer trial with FDA approval, adding 10 patients for a combination treatment approach.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.